Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference | ||
By: PR Newswire Association LLC. - 18 Mar 2024 | Back to overview list |
|
DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024. Brenig's innovative approach to the rationally designed LRRK2 inhibitor (BT-0267) marks a significant stride in the company's mission to combat neurodegenerative diseases. LRRK2, a key protein implicated in Parkinson's disease (PD), has been a challenging therapeutic target. Brenig's cutting-edge research has culminated in the development of a candidate with a highly efficient blood-brain barrier penetration, minimal peripheral exposure, as well as a superior overall safety profile. Brenig's breakthrough efforts in developing the best-in-class LRRK2 inhibitor for the disease modifying treatment of PD population, including idiopathic PD (iPD) cases, have been supported by the cutting-edge computer-aided drug design and structural biology expertise of Expert Systems Accelerator. About Brenig Therapeutics Brenig Therapeutics is a European science-based venture dedicated to pioneering breakthrough treatments for neurodegenerative diseases. With a focus on developing innovative therapies, Brenig is committed to advancing the field of neurology through cutting-edge research and strategic partnerships. For further information, please contact: Alexei Pushechnikov, PhD View original content:https://www.prnewswire.com/news-releases/brenig-therapeutics-presented-new-data-for-the-best-in-class-lrrk2-inhibitor-targeting-parkinsons-disease-at-the-acs-spring-2024-conference-302091628.html SOURCE Brenig Therapeutics |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |